← Eichor
Study identifier: NCT07312110 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression

Condition: Parkinson s Disease · Parkinson Disease (PD)  ·  Sponsor: Haukeland University Hospital

PhasePhase 2
Planned participants100
Who can joinAll sexes, 40 Years to 80 Years
Healthy volunteersNo

About this study

This clinical study, designed as a randomized, double-blind, placebo-controlled trial, aims to investigate if modulation of the N-methyl-D-aspartate receptor (NMDAR) via its co-agonist D-serine has therapeutic benefits in Parkinson's disease (PD). All patients will receive both placebo and D-serine over different time periods during the study. Preclinical studies have shown that blocking glycine transporters, which elevates endogenous glycine levels, can restore NMDAR function and improve motor deficits in PD models. A clinical trial demonstrated that oral D-serine (30 mg/kg/day for 6 weeks) significantly reduced extrapyramidal and abnormal involuntary movements in PD patients compared to placebo, with improvements observed in both motor and non-motor symptoms. D-serine supplementation has shown an acceptable safety profile with doses up to 120 mg/kg showing no significant adverse effects in clinical studies. The D-SPARK trial primarily aims to determine the efficacy of D-serine supplementation on clinical severity of PD as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Secondary aims are to determine the efficacy of D-serine supplementation on improving dopaminergic nigrostriatal innervation as measured by single-photon emission tomography (SPECT) based imaging of the dopamine transporter (DaT-scan) and cognition as measured by the California Verbal Learning Test version 2 (CLVT-II). The study will include 100 persons with…

This description comes directly from the study's public registry record.

Talk to the study team

Charalampos Tzoulis, MD, PhD  ·  55975061  ·  charalampos.tzoulis@helse-bergen.no

Haakon Berven, MD  ·  55975045  ·  haakon.berven@helse-bergen.no

Always discuss trial participation with your own doctor first.

Locations (11)

Nevro Arendal SoerlandsklinikkenArendal, Agder, NorwayRecruiting
Akershus University HospitalLørenskog, Akershus, NorwayNot Yet Recruiting
Vestre Viken HospitalDrammen, Buskerud, NorwayNot Yet Recruiting
Molde HospitalMolde, Møre og Romsdal, NorwayNot Yet Recruiting
Bodø Hospital (Nordland Hospital)Bodø, Nordland, NorwayNot Yet Recruiting
Oslo University HospitalOslo, Oslo, NorwayRecruiting
Haugesund HospitalHaugesund, Rogaland, NorwayNot Yet Recruiting
University Hospital of North NorwayTromsø, Troms, NorwayNot Yet Recruiting
Haukeland University HospitalBergen, Vestland, NorwayRecruiting
Førde HospitalFørde, Vestland, NorwayNot Yet Recruiting
Østfold HospitalSarpsborg, Østfold fylke, NorwayNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07312110